Australian clinical-stage biotechnology company Immutep (ASX:IMM) has announced that the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with first-line non-small cell lung cancer (NSCLC).
The company is developing novel LAG-3 immunotherapies for cancer and autoimmune diseases.
INSIGHT-003 is the first trial evaluating Immutep's lead product candidate, eftilagimod alpha (efti) as part of a triple combination therapy with standard-of-care anti-PD-1 therapy (MSD's KEYTRUDA) and chemotherapy.
Immutep's Dr Frederic Triebel said, "The promising initial efficacy and favourable safety results reported in November 2022 from this first triple combination approach instils more confidence in the flexibility of our novel immunotherapy, efti to be combined with various therapeutics and safely drive superior patient outcomes.
"We are pleased to have reached our enrolment target and look forward to reporting as the results mature further. Additional data from INSIGHT-003 will help further inform our next steps in 1st line NSCLC."
The company said the additional data from INSIGHT-003 is expected to be presented during the calendar year 2023.
